Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
80
resultados
Última actualización
28/02/2026 [06:45:00]
Resultados 25 a 50 de 80
Resumen de: WO2026030836A1
Use of Placenta Hominis in the preparation of an anti-cancer drug. Water extraction is one of extraction methods for Placenta Hominis. Placenta Hominis can treat various cancers, such as lymphoma, leukemia, skin cancer, lung cancer, breast cancer, liver cancer, gastric cancer, pancreatic cancer, rectal cancer, brain cancer, kidney cancer, bladder cancer, etc., by improving human immunity.
Resumen de: AU2024294949A1
Provided are methods of treating a subject having a hematologic malignancy or pre-malignancy that involve administering an effective amount of olutasidenib, venetoclax, and a hypomethylating agent. In some cases, the patient has an IDH1 mutation.
Resumen de: WO2026035999A1
Provided are compounds of the structural Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.
Resumen de: US20260042752A1
Provided are compounds of the structural Formula (I):and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.
Resumen de: US20260042861A1
Provided are formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof. The formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa·s, and the pH of the solution is 5.9 to 7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations will find use in treating CD38+ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans.
Resumen de: WO2026032322A1
Disclosed in the present application is the use of a compound of formula I in the preparation of a drug for treating the following tumors, which are selected from gastric cancer, esophageal cancer, cholangiocarcinoma, nasopharyngeal cancer, soft tissue sarcoma, prostate cancer, liver cancer, non-small cell lung cancer, breast cancer, glioma, leukemia, ovarian cancer, cervical cancer, endometrial carcinoma, primary brain tumors, brain metastatic tumors, pancreatic cancer and angiosarcoma. Further disclosed is the use of the compound in combination with other anti-tumor drugs in the treatment of the above-mentioned cancers.
Resumen de: WO2026035974A1
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.
Resumen de: WO2026033458A1
The present disclosure relates to doses and dosing regimens of a bispecific antibody that binds myeloid cell surface antigen CD33, and the Vδ2 chain of the human Vγ9Vδ2 T cell receptor; to pharmaceutical compositions comprising said antibodies, as well as methods of administration of the referred doses, and to the use of said antibodies in the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Neoplasms (MDS), in particular Relapsed or Refractory (R/R) AML or MDS.
Resumen de: US20260041768A1
Provided herein are methods of treating cancer in a subject in need thereof by administering an anti-BCMA CAR-T cell and a GPRC5D×CD3 bispecific antibody. In some embodiments, the subject has relapsed and/or refractory multiple myeloma. In some embodiments, the subject has received at least one prior line of therapy. In some embodiments, the subject has newly diagnosed multiple myeloma and is transplant ineligible.
Resumen de: US20260041719A1
This document relates to methods and materials involved in assessing and/or treating a mammal having cancer (e.g., lymphoma). For example, methods and materials that can be used to determine if a mammal (e.g., a human) having cancer (e.g., lymphoma) is likely to respond to or has a cancer or a gut microbiome that makes that mammal more responsive to a particular cancer treatment are provided. Methods and materials for treating a mammal having cancer (e.g., lymphoma) are also provided.
Resumen de: US20260041647A1
Provided are compositions that include histone deacetylase (HDAC) inhibitors encapsulated in and/or otherwise associated with detectable nanoparticles, and methods for using the same in medical and veterinary applications including but not limited to treating diseases, disorders, and/or conditions associated with sensitivity to HDAC inhibitors; inhibiting the growth, proliferation, and/or metastasis of a tumor and/or a cancer associated with sensitivity to HDAC inhibitors, and for treating inflammatory and/or an autoimmune diseases, disorders, and/or conditions associated with sensitivity to HDAC inhibitors. Also provided are methods for imaging cells, tissues, organs, and/or other targets in subject.
Resumen de: US20260042853A1
IL2-CCR4 bispecific immunotoxin, CCR4-IL2 bispecific immunotoxin, and methods of use thereof for treatment of refractory and recurrent human CD25.sup.+ and/or CCR4.sup.+ cutaneous T cell lymphoma, and other human CD25.sup.+ or CCR4.sup.+ tumors. The bispecific immunotoxin can be also used for broad cancer treatment via depleting CD25.sup.+ or CCR4.sup.+ Tregs.
Resumen de: US20260042835A1
This disclosure relates to methods for treating cancer in a subject identified as having chronic myelomonocytic leukemia (CMML), comprising administering an anti-ILT3 antigen binding protein, or antigen binding fragment to the patient every three weeks (Q3W).
Resumen de: EP4692331A1
An object of the present invention is to provide a novel cell used for detecting a pyrogenic substance by a MAT method, a method of detecting a pyrogenic substance in a specimen using the cell, and a kit for use in detecting a pyrogenic substance, containing the cell. According to the present invention, there are provided a cell which is derived from any one of a promonocyte-like cell line NOMO-1, a human-derived monocyte cell line U-937, a human-derived monoblast cell line GDM-1, a human-derived monocyte/macrophage cell line 28SC-ES, or a multiple myeloma cell line RPMI8226, in which at least one reporter gene, expression of which is controlled by a promoter inducible by NF-κB, has been introduced into the cell, and the cell has a toll-like receptor; a method for detecting a pyrogenic substance in a specimen using the cell; and a kit for use in detecting a pyrogenic substance, containing the cell.
Resumen de: EP4692125A2
The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
Resumen de: EP4691495A1
The present disclosure discloses a use of a drug combination containing an anti-CD20 antibody drug conjugate (ADC) in the preparation of a drug for treating Non-Hodgkin Lymphoma (NHL). The drug combination includes the anti-CD20 ADC and at least one therapeutic agent. The drug combination therapy has better efficacy than the existing clinical first-line standard therapy. Additionally, it offers several advantages, including fewer types of drugs, shorter infusion time, lower safety risks, and better economic accessibility.
Resumen de: US20260034176A1
The present disclosure provides, among other things, methods for treating relapsed or refractory acute myeloid leukemia by administering to a subject in need thereof a therapeutically effective amount of an allogeneic composition comprising VDelta1+ (Vδ1+) gamma delta (γδ) T cells such that one or more symptoms or biomarkers is improved after treatment. The present disclosure also provides suitable doses of compositions comprising allogeneic Vδ1+gamma delta (γδ) T cells for administration to a subject suffering from relapsed or refractory AML. In some embodiments, the Vδ1+gamma delta (γδ) T cells are untransduced.
Resumen de: US2025276961A1
Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.
Resumen de: AU2026200119A1
22350466_1 (GHMatters) P106885.AU.2 Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti- CD79b antibodies in combination with additional therapeutic agents. an a n
Resumen de: US20260034176A1
The present disclosure provides, among other things, methods for treating relapsed or refractory acute myeloid leukemia by administering to a subject in need thereof a therapeutically effective amount of an allogeneic composition comprising VDelta1+ (Vδ1+) gamma delta (γδ) T cells such that one or more symptoms or biomarkers is improved after treatment. The present disclosure also provides suitable doses of compositions comprising allogeneic Vδ1+gamma delta (γδ) T cells for administration to a subject suffering from relapsed or refractory AML. In some embodiments, the Vδ1+gamma delta (γδ) T cells are untransduced.
Resumen de: US20260035459A1
The present invention provides humanized chimeric antigen receptors (CARs) targeting the B-cell receptor (BCR) of CLL cells characterised by R110-mutated immunoglobulin lambda variable 3-21 (IGLV3-21R110).The Invention also provides nucleic acid sequences encoding the forgoing CARs, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
Resumen de: US20260034218A1
We have discovered that allogeneic HSC-engineered human iNKT (3rdHSC-iNKT) cells display potent anti-GvHD functions, by eliminating antigen-presenting myeloid cells in vitro and in xenograft models, without negatively impacting tumor eradication by allogeneic T cells in preclinical models of lymphoma and leukemia. The 3rdHSC-iNKT cells closely resembled the CD4−CD8−/+ subsets of endogenous human iNKT cells in phenotype and functionality. Embodiments of the invention harness these discoveries in new methods and materials for alleviating graft versus host disease.
Resumen de: US20260034217A1
The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.
Resumen de: US20260034102A1
There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof:a combination of said compound of formula I or a pharmaceutically acceptable salt thereof with Brentuximab Vedotin and said combination for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said combination.
Nº publicación: US20260034112A1 05/02/2026
Solicitante:
CHILDRENS HOSPITAL MEDICAL CENTER [US]
THE US SECRETARY DEPT OF HEALTH AND HUMAN SERVICES [US]
KUROME THERAPEUTICS INC [US]
CHILDREN'S HOSPITAL MEDICAL CENTER,
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES,
KUROME THERAPEUTICS, INC
Resumen de: US20260034112A1
The present disclosure provides a method of treating an inflammatory disease/disorder, acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS) in a subject comprising administering to the subject a compound that inhibits IRAK1 and IRAK4. The present disclosure further provides a method of determining a compound that is effective at treating an inflammatory disease/disorder, AML, or MDS.
BOPI
Sede Electrónica
